<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653103</url>
  </required_header>
  <id_info>
    <org_study_id>20202011</org_study_id>
    <nct_id>NCT04653103</nct_id>
  </id_info>
  <brief_title>NASH in Subjects With Different Classes of Obesity</brief_title>
  <acronym>CONNECT</acronym>
  <official_title>Prevalence of NASH in Subjects With Different Classes of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is an observational trial on 500 subjects. The purpose of this trial is to assess the&#xD;
      prevalence of non-alcoholic steatohepatitis (NASH) in subjects with different classes of&#xD;
      obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic&#xD;
      liver disease due to an increase in the prevalence of obesity. The development of NASH leads&#xD;
      to an increase in morbidity and mortality. Since patients with obesity are at an increased&#xD;
      risk of NASH, the aim of this trial is to assess the prevalence of NASH in this class of&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">January 25, 2023</completion_date>
  <primary_completion_date type="Actual">January 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of NASH</measure>
    <time_frame>6 months</time_frame>
    <description>Prevalence of NASH in a cohort of patients with different classes of obesity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of lipid profile</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of triglycerides, total cholesterol, LDL and HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of glycemic profile</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of glycated hemoglobin</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of glycated hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of liver enzymes</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of AST, ALT, GGT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of insulin</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of metabolic profile</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of HOMA-IR index</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>NAFLD</condition>
  <condition>Obesity</condition>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>Patients with obesity</arm_group_label>
    <description>Subjects with different classes of obesity</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver biopsy</intervention_name>
    <description>Biopsy of the liver to assess for Non-alcoholic steatohepatitis</description>
    <arm_group_label>Patients with obesity</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with different classes of obesity&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 19 and 69 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  End stage renal failure&#xD;
&#xD;
          -  End stage liver failure&#xD;
&#xD;
          -  Being unable to understand and sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geltrude Mingrone, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of the Sacred Heart</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rome Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University School of Medicine</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Geltrude Mingrone</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

